Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
PLoS One ; 18(5): e0277279, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37235625

RESUMO

BACKGROUND: Evidence-based empirical antibiotic prescribing requires knowledge of local antimicrobial resistance patterns. The spectrum of pathogens and their susceptibility strongly influences guidelines for empirical therapies for urinary tract infections (UTI) management. OBJECTIVE: This study aimed to determine the prevalence of UTI causative bacteria and their corresponding antibiotic resistance profiles in three counties of Kenya. Such data could be used to determine the optimal empirical therapy. METHODS: In this cross-sectional study, urine samples were collected from patients who presented with symptoms suggestive of UTI in the following healthcare facilities; Kenyatta National Hospital, Kiambu Hospital, Mbagathi, Makueni, Nanyuki, Centre for Microbiology Research, and Mukuru Health Centres. Urine cultures were done on Cystine Lactose Electrolyte Deficient (CLED) to isolate UTI bacterial etiologies, while antibiotic sensitivity testing was done using the Kirby-Bauer disk diffusion using CLSI guidelines and interpretive criteria. RESULTS: A total of 1,027(54%) uropathogens were isolated from the urine samples of 1898 participants. Staphylococcus spp. and Escherichia coli were the main uropathogens at 37.6% and 30.9%, respectively. The percentage resistance to commonly used drugs for the treatment of UTI were as follows: trimethoprim (64%), sulfamethoxazole (57%), nalidixic acid(57%), ciprofloxacin (27%), amoxicillin-clavulanic acid (5%), and nitrofurantoin (9%) and cefixime (9%). Resistance rates to broad-spectrum antimicrobials, such as ceftazidime, gentamicin, and ceftriaxone, were 15%, 14%, and 11%, respectively. Additionally, the proportion of Multidrug-resistant (MDR) bacteria was 66%. CONCLUSION: High resistance rates toward fluoroquinolones, sulfamethoxazole, and trimethoprim were reported. These antibiotics are commonly used drugs as they are inexpensive and readily available. Based on these findings, more robust standardised surveillance is needed to confirm the patterns observed while recognising the potential impact of sampling biases on observed resistance rates.


Assuntos
Antibacterianos , Infecções Urinárias , Humanos , Antibacterianos/farmacologia , Antibacterianos/uso terapêutico , Quênia/epidemiologia , Estudos Transversais , Farmacorresistência Bacteriana , Infecções Urinárias/tratamento farmacológico , Infecções Urinárias/epidemiologia , Infecções Urinárias/microbiologia , Bactérias , Trimetoprima/uso terapêutico , Escherichia coli , Sulfametoxazol , Instalações de Saúde , Testes de Sensibilidade Microbiana
2.
Biomédica (Bogotá) ; 34(supl.1): 9-15, abr. 2014.
Artigo em Inglês | LILACS | ID: lil-712416

RESUMO

The microbes that infect us spread in global and local epidemics, and the resistance genes that block their treatment spread within and between them. All we can know about where they are to track and contain them comes from the only places that can see them, the world´s microbiology laboratories, but most report each patient´s microbe only to that patient´s caregiver. Sensors, ranging from instruments to birdwatchers, are now being linked in electronic networks to monitor and interpret algorithmically in real-time ocean currents, atmospheric carbon, supply-chain inventory, bird migration, etc. To so link the world´s microbiology laboratories as exquisite sensors in a truly lifesaving real-time network their data must be accessed and fully subtyped. Microbiology laboratories put individual reports into inaccessible paper or mutually incompatible electronic reporting systems, but those from more than 2,200 laboratories in more than 108 countries worldwide are now accessed and translated into compatible WHONET files. These increasingly web-based files could initiate a global microbial sensor network. Unused microbiology laboratory byproduct data, now from drug susceptibility and biochemical testing but increasingly from new technologies (genotyping, MALDI-TOF, etc.), can be reused to subtype microbes of each genus/species into sub-groupings that are discriminated and traced with greater sensitivity. Ongoing statistical delineation of subtypes from global sensor network data will improve detection of movement into any patient of a microbe or resistance gene from another patient, medical center or country. Growing data on clinical manifestations and global distributions of subtypes can automate comments for patient´s reports, select microbes to genotype and alert responders.


.


Assuntos
Humanos , Infecções Bacterianas/tratamento farmacológico , Farmacorresistência Bacteriana , Saúde Global , Disseminação de Informação , Cooperação Internacional , Serviços de Informação/organização & administração , Laboratórios/organização & administração , Antibacterianos/administração & dosagem , Antibacterianos/uso terapêutico , Boston , Bactérias/classificação , Bactérias/efeitos dos fármacos , Infecções Bacterianas/epidemiologia , Técnicas de Tipagem Bacteriana/métodos , Sistemas Computacionais , Coleta de Dados , Bases de Dados Factuais , Registros Eletrônicos de Saúde , Monitoramento Epidemiológico , Mapeamento Geográfico , Hospitais Universitários/organização & administração , Internet , Serviços de Informação/tendências , Laboratórios/tendências , Software , Espectrometria de Massas por Ionização e Dessorção a Laser Assistida por Matriz , Organização Mundial da Saúde/organização & administração
3.
Drug Resist Updat ; 14(2): 79-87, 2011 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-21482177

RESUMO

The foreseen decline in antibiotic effectiveness explains the needs for data to inform the global public health agenda about the magnitude and evolution of antibiotic resistance as a serious threat to human health and development. Opportunistic bacterial pathogens are the cause of the majority of community and hospital-acquired infections worldwide. We provide an inventory of pre-existing regional surveillance programs in the six WHO regions which should form the underpinning for the consolidation of a global network infrastructure and we outline the structural components such as an international network of reference laboratories that need to be put in place to address the void of these crucial data. In addition we suggest to make use of existing Health and Demographic Surveillance Sites (HDSS) to obtain crucial information from communities in resource limited settings at household level in low- and middle-income countries in Asia and Africa. For optimising the use of surveillance data for public health action i.e. priority setting for new drug development, comparative quantification of antibiotic effectiveness at local, national, regional and global level and identification of the action gaps can be helpful.


Assuntos
Antibacterianos/uso terapêutico , Infecções Bacterianas/epidemiologia , Indústria Farmacêutica/economia , Resistência Microbiana a Medicamentos , Pandemias/prevenção & controle , Vigilância da População , Antibacterianos/síntese química , Bactérias/patogenicidade , Infecções Bacterianas/tratamento farmacológico , Infecções Bacterianas/microbiologia , Países em Desenvolvimento , Descoberta de Drogas , Indústria Farmacêutica/organização & administração , Humanos , Internacionalidade , Vigilância da População/métodos , Prevalência , Saúde Pública , Organização Mundial da Saúde
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA